Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Charles River Laboratories International Inc. will pay the U.S. government $1.8 million to settle charges that it violated the False Claims Act by over-billing for costs on NIH contracts, the Justice Department announced March 13.
According to the DOJ, Charles River billed the National Institutes of Health for labor and associated costs of employees at its Raleigh, N.C., and Kingston, N.Y., facilities, who didn’t render the services as Charles River had claimed.
Charles River is a Wilmington, Mass.-based contract research organization and holds contracts with the NIH for services relating to the development, maintenance and distribution of colonies of animals as well as the provision of laboratory animals.
The FCA is the government’s primary civil remedy to redress false claims for government funds and property under government programs and contracts. In December, the DOJ said it had recovered $2.15 billion in 2016 from the health care sector—biopharmas, medical device companies, laboratories, hospitals and physicians—in settlement payments for allegations of FCA violations.
The DOJ said the Charles River claims settled by the agreement are allegations only and there has been no determination of liability.
Charles River investigated concerns about inaccurate billing for certain federal contracts with the assistance of the law firm of Davis, Polk & Wardwell LLP, Amy Cianciaruso, Charles River’s corporate vice president for public relations and corporate communications, told Bloomberg BNA in a March 14 email. It reported the problem to the appropriate federal agencies and ensured the proper repayment and resolution of the issue, she said.
“Based on the findings of the investigation and confirmation that this overbilling was confined to a limited amount of work performed at two of our research model facilities, we were able to cooperatively resolve this matter to the government’s full satisfaction,” Cianciaruso said.
The DOJ statement noted that Charles River reported the improper billing to the DOJ and the Department of Health and Human Services, of which the NIH is a part.
“Charles River’s self-disclosure and resolution of this matter underscores the importance of contractors preventing, detecting, and remediating overcharges of labor costs to HHS. Under our contractor self-disclosure program, OIG is committed to working with HHS contractors that detect fraud issues to review, take any appropriate action, and resolve these matters fairly” Gregory E. Demske, chief counsel to the inspector general, HHS Office of Inspector General, said in the statement.
Charles River, which has about 8,000 employees worldwide, reported annual global revenue of $1.3 billion in its 2015 annual report. The DOJ announcement was made the same day Charles River announced it has extended its longstanding, strategic, integrated drug discovery partnership with the Parma, Italy-based Chiesi Farmaceutici SpA in the field of respiratory disease.
The Charles River-NIH relationship has raised issues before with federal investigators. In 2011, the HHS OIG determined the NIH’s five-year, $27.1 million contract with Charles River to provide research laboratory technical services and animal care didn’t comply with appropriations statutes in terms of the time and amount of the contracts ().
In January 2014, Charles River was one of 12 companies that agreed to no-fault consent orders with the Federal Trade Commission to settle commission charges they falsely claimed they were in compliance with the U.S.-European Union and U.S.-Switzerland Safe Harbor programs, although they had let their certifications lapse, These programs concern the transfer of consumer data.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)